Evidence map›Paper›PMID 28115846›Full record

ArticleInternational journal of nanomedicine2017

Preparation of arginine-glycine-aspartic acid-modified biopolymeric nanoparticles containing epigalloccatechin-3-gallate for targeting vascular endothelial cells to inhibit corneal neovascularization.

Che-Yi Chang, Ming-Chen Wang, Takuya Miyagawa, Zhi-Yu Chen, Feng-Huei Lin, Ko-Hua Chen, Guei-Sheung Liu, Ching-Li Tseng

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of nanomedicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
2.8field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 54 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Available Therapeutic Options for Corneal Neovascularization: A Review.International journal of molecular sciences · 2024
    Review
  8. Review
  9. Review
  10. Article
  11. Review
  12. Investigating Polyphenol Nanoformulations for Therapeutic Targets against Diabetes Mellitus.Evidence-based complementary and alternative medicine : eCAM · 2022
    Review
  13. Article
  14. Article
  15. Ocular Delivery of Polyphenols: Meeting the Unmet Needs.Molecules (Basel, Switzerland) · 2021
    Review
  16. Article
  17. Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Che-Yi ChangGraduate Institute of Biomedical Materials and Tissue Engineering, College of Biomedical Engineering, Taipei Medical University, Taipei; Department of Biomedical Engineering, Chung Yuan Christian University, Taoyuan.
Ming-Chen WangDepartment of Biomedical Engineering, Chung Yuan Christian University, Taoyuan.
Takuya MiyagawaGraduate Institute of Biomedical Materials and Tissue Engineering, College of Biomedical Engineering, Taipei Medical University, Taipei.
Zhi-Yu ChenGraduate Institute of Biomedical Materials and Tissue Engineering, College of Biomedical Engineering, Taipei Medical University, Taipei.
Feng-Huei LinInstitute of Biomedical Engineering and Nanomedicine, National Health Research Institutes, Zhunan; Institute of Biomedical Engineering, National Taiwan University.
Ko-Hua ChenDepartment of Ophthalmology, Taipei Veterans General Hospital; Department of Ophthalmology, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan.
Guei-Sheung LiuCentre for Eye Research Australia, University of Melbourne, Royal Victorian Eye and Ear Hospital, East Melbourne, VIC, Australia.
Ching-Li TsengGraduate Institute of Biomedical Materials and Tissue Engineering, College of Biomedical Engineering, Taipei Medical University, Taipei.
Taipei Medical University · TWChung Yuan Christian University · TWUniversity of Melbourne · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Neovascularization (NV) of the cornea can disrupt visual function, causing ocular diseases, including blindness. Therefore, treatment of corneal NV has a high public health impact. Epigalloccatechin-3-gallate (EGCG), presenting antiangiogenesis effects, was chosen as an inhibitor to treat human vascular endothelial cells for corneal NV treatment. An arginine-glycine-aspartic acid (RGD) peptide-hyaluronic acid (HA)-conjugated complex coating on the gelatin/EGCG self-assembly nanoparticles (GEH-RGD NPs) was synthesized for targeting the α

Indexed as

Angiogenesis InhibitorsAnimalsBurns, ChemicalCatechinCell SurvivalCorneal NeovascularizationDisease Models, AnimalEye BurnsHumansHuman Umbilical Vein Endothelial CellsHyaluronic AcidIntegrin alphaVbeta3Mice, Inbred C57BLMolecular Targeted TherapyNanoparticlesOligopeptidesAngiogenesis Inhibitorsarginyl-glycyl-aspartic acidCatechinepigallocatechin gallateHyaluronic AcidIntegrin alphaVbeta3OligopeptidesOphthalmic Solutionsantiangiogenesiscorneal neovascularizationepigallocatechin gallate (EGCG)hyaluronic acid (HA)RGD peptidevascular endothelial cells

Identifiers

PMID28115846
PMCPMC5221810
OpenAlexW2565395257

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.